secwatch.observer — SEC 8-K summary
======================================

Issuer:     TScan Therapeutics, Inc. (TCRX)
CIK:        0001783328
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063959
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TScan Q1 net loss $34.1M; cash runway into Q1 2027; registrational trial H2 2025
--------------------------------------------------------------------------------

- Revenue $2.2M (up from $0.6M YoY); R&D expense $29.8M; net loss $34.1M vs $30.1M YoY.
- Cash, equivalents, and marketable securities $251.7M (plus $5.0M restricted) funding operations into Q1 2027.
- On track to initiate registrational trial for TSC-101 and file IND for TSC-102-A0301 in H2 2025.
- First patient dosing with multiplex TCR-T therapy expected H1 2025; safety/efficacy data by year-end.
- Appointed Stephen Camiolo as SVP Market Access; presenting at ASGCT and Bank of America conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1783328/000095017025063959/0000950170-25-063959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1783328/000095017025063959/tcrx-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer